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A 59-year-old man visited our hospital in June 1997 because of cough and dyspnea at
rest.  He was diagnosed as pulmonary alveolar proteinosis (PAP) by bronchoalveolar
lavage (BAL) and transbronchial lung biopsy.  The alveoli were distended with pink
homogeneous material that showed staining with the periodic acid Schiff method.  The
concentration of surfactant protein A in BAL fluid was significantly increased.  We
treated the patient with oral ambroxol hydrochloride and therapeutic BAL.  We believe
that this combination of therapies is the first choice for the treatment of PAP.
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Pulmonary alveolar proteinosis (PAP) is char-
acterized by the  presence of copious eosino-
philic, periodic acid Schiff (PAS)-positive ma-
terial in the alveoli and by an excess of surfac-
tant components (both lipids and proteins) in
lung lavage.  It may be present during the neo-
natal period or later in life.  PAP is the conse-
quence of a genetic defect involving the lungs,
such as a mutation of the surfactant protein B
(SP-B) gene, or it can represent an aspect of a
different genetic disease, such as lysinuric pro-
tein intolerance.  PAP may also be associated
with infections, malignancies, exposure to
dusts, or the use of certain drugs.  In most cases,
however, it occurs as an isolated entity with no
apparent cause, and is known as idiopathic al-
veolar proteinosis (Antonella et al., 1996).  The
cause is likely related to either overstimulation
of type II pneumocytes or an impairment of the
mechanism for removal of alveolar phospho-
lipids (Cesar et al., 1995).  In the alveoli of pa-
tients with PAP, the alveolar clearance of pro-
teinaceous materials is impaired.  Many investi-
gators have reported biochemical studies of
bronchoalveolar lavage (BAL) fluid in the pa-
tients with PAP, including analyses of proteins
and phospholipids (Sahu et al., 1976; Akino et
al, 1978; Onodera et al., 1983; Honda et al.,
1989).  Amounts of protein and phospholipid
were found to be significantly increased relative
to those in contrast to normal subjects.  Surfac-
tant protein A (SP-A) is the predominant phos-
pholipid-associated glycoprotein in pulmonary
surfactant and is specific to the lung.  The con-
tents of SP-A in BAL fluid can be measured to
diagnose PAP (Honda et al., 1993).  We report a
case of PAP diagnosed by an increase of SP-A
in BAL fluid, and treated by oral ambroxol
hydrochloride and BAL.
Patient report
A 59-year-old Japanese man who lives in Tottori
Prefecture, Japan was admitted to our hospital
in June 1997 because of cough and dyspnea at
rest.  His past medical history included 2 ad-
missions for pneumonia in 1994 and 1995.  He
had smoked 20 cigarettes per day for over 30
years and had been employed as a garbage man
of a building for over 18 years.
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Although physical examination on admis-
sion showed respiratory distress, he complained
only of mild dyspnea.  He had a non-productive
cough.  Auscultation of the lung showed coarse
inspiratory crackles in both lung fields.  There
was mild clubbing of the nail beds.  The labora-
tory findings showed high levels of lactic acid
dehydrogenase (421 IU/L), C-reactive protein
(1.27 mg/dL) and carcinoembryonic antigen
(7.3 ng/mL).  Sputum cultures for bacteria, fun-
gi and tuberculosis were negative.  His chest
radiograph showed diffuse
bilateral interstitial re-
ticular and alveolar den-
sities of both lung fields.
Computed tomography of
the chest showed diffuse,
non-segmental densities of
various degrees, with a pe-
ripheral clear zone, primar-
ily in the mid-lung field,
and honeycombing shadows
in the lower lung field (Fig.
1a).  Analysis of arterial
blood gases showed hypo-
xia (arterial oxygen pres-
sure, 54.1 mm Hg).  On the
3rd day after admission, the
patient developed respira-
tory failure.  BAL was per-
formed on the right B4 seg-
Fig. 1b.  Computed tomogram of the chest  obtained after oral admin-
istration of ambroxol hydrochroloride and therapeutic bronchoalveolar
lavage (BAL).
ment and a transbronchial
lung biopsy was performed
on the right B4 and B8 seg-
ments.  The specimens were
stained with hematoxylin
and eosin.  Light microsco-
py of the transbronchial lung
biopsy showed distended
alveoli with a pink homoge-
neous material that was
PAS-positive, and slight
thickening of the alveolar
walls with minimal infil-
tration of lymphocytes (Fig.
2a).  Immunostaining for SP-
A of lung biopsy specimens
resulted in positive staining
(Fig. 2b).  No atypical lym-
phocytes were detected in the infiltrating cells.
The BAL fluid contained phospholipid and was
sent to Sapporo Medical College, Sapporo,
Japan to measure SP-A.  The concentration of
SP-A in the BAL fluid was significantly in-
creased at 482.2 m g/mL (normal range, 1.3 to
5.2 m g/mL).  Also the ratio of SP-A to phos-
pholipid was 3.58 m g/nmol (normal range, 0.05
to 0.11 m g/nmol) (Honda et al., 1993).  There-
fore, we made a diagnosis of PAP, and treated
the patient with oral ambroxol hydrochloride
Fig. 1a.  Computed tomogram of the chest on admission.
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consists of lipid bilayer membranes separated
by amorphous proteinaceous material contain-
ing phospholipids and proteins similar to sur-
factant or one of its components.  The lung sur-
factant system is a mixture of phospholipids
and protein synthesized and secreted in the al-
veolar spaces primarily by type II pneumocytes.
Its main function is the reduction of surface ten-
sion to insure stability of alveolar units.  Sur-
factant is also thought to be involved in mucus
transport and to interact with the pulmonary
defense system (Luisetti  et
al., 1987).  SP-A is a major
hydrophilic (28 to 36 kDa)
glycoprotein of pulmonary
surfactant and is specific
for pulmonary surfactant,
synthesized by type II cells
and secreted into the alveo-
lar space.  An immunohisto-
chemical study using a
polyclonal antibody to sur-
factant-specific apoprotein
has demonstrated that SP-
A is a useful immunohisto-
chemical marker for the
diagnosis of PAP (Honda et
al., 1993).  In our case, the
concentration of SP-A in
(45 mg/day) and thera-
peutic BAL.  BAL was per-
formed weekly with 100 to
150 mL of saline instilled
through a fiberoptic bron-
choscope into a segmental
bronchus under local anes-
thesia.  The recovered la-
vage fluid was initially
milky, and the lavage was
repeated until the fluid  be-
came clear.  After 3 series
of therapeutic lavages, his
radiographic infiltrates
have cleared significantly
(Fig. 1b).  He is now living
and well 2 years following
our treatment with no evi-
dence of recurrence of the
disease.
Discussion
PAP is characterized by the deposition of pro-
teinaceous material in air spaces, originally de-
scribed in 1958 (Roen et al., 1958).  Associated
conditions include immunocompromised states,
which suggests that malfunction of alveolar
macrophages allow for the accumulation of ab-
normal intra-alveolar material.  This material
Fig. 2a.  Photomicrograph of lung biopsy.  Alveolar spaces are filled with
dense, periodic acid Schiff (PAS)-positive and proteinaceous material.
Alveolar septa are thin throughout the section.  PAS stain, ·  400.
Fig. 2b.  Immunostaining for surfactant protein A (SP-A) of lung biopsy
specimens shows positivity, ·  100.
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BAL fluid was significantly higher, confirming
the diagnosis of PAP.
The established treatment of choice for PAP
is therapeutic whole lung lavage (WLL), per-
formed under general anesthesia, although this
method may be associated with severe hypoxia.
After such WLL, migration of alveolar macro-
phages increases to supernormal levels, and
subsequent clinical relapse is associated with a
decreased level of migration.  These results sup-
port the conclusion of a previous study that the
abnormal alveolar macrophage function in PAP
is an acquired defect (Robert et al., 1989).
Problems with WLL include hypoxia, flood-
ing of the contralateral lung, ipsilateral hydro-
thorax, airway trauma, hypothermia and elec-
trolyte disequilibrium, and thus WLL requires a
trained and experienced staff of physicians and
nurses (Rodi et al., 1995).  So this technique
must be reserved for clinically progressive
forms of the disease and for experienced hands
(Diaz et al., 1984).  In our patient, after treat-
ment with oral ambroxol hydrochloride and
therapeutic BAL the radiographic infiltrates
have cleared.
The main pharmacodynamic effects of
ambroxol hydrochloride are surfactant stimula-
tion, mucokinetic activity and some secreta-
gogue activity (Karl, 1987).  The lung surfac-
tant system is a mixture of phospholipids and
protein synthesized and secreted in the alveolar
spaces primarily by type II pneumocytes.  So
type II pneumocyte stimulation with ambroxol
hydrochloride can lead to chemico-physical and
functional changes in alveolar macrophages,
probably through an increase in surfactant
secretion and uptake (Luisetti et al., 1987).
Thus, we propose that oral ambroxol hydro-
chloride and  therapeutic BAL should be the
first choice in treating PAP.
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